Sentiment Analysis of the earnings transcript to help figure out if there are any bullish or bearish sentiments that could be gathered from it. We're doing ML and AI based analysis on the earnings call to get some more insights.
Please consider a small donation if you think this website provides you with relevant information
| Statement |
|---|
| Our team has been working diligently, and I'm very pleased with all the progress we've made to prepare for the potential emergency use authorization, and we are excited for the potential launch of VYD222 in 2024, if authorized |
| I'm very proud of the impressive progress that our team and our study partners have made this quarter to advance our CANOPY trial |
| I've been very impressed by the Invivyd team's ability to execute to plan and by the nimble, highly motivated teams that are driving Invivyd's work forward at a remarkable pace |
| We have also started manufacturing of VYD222 commercial inventory with WuXi, and they continue to be an outstanding partner to us as we make excellent progress preparing for the CMC package that will be part of our anticipated EUA submission |
| This is a very exciting time for Invivyd as we approach a potential EUA submission and authorization of VYD222 for the prevention of symptomatic COVID-19, which would represent a significant achievement for Invivyd |
| I am tremendously proud of the progress our team has made this year executing to plan |
| I see great potential in Invivyd's strategy and platform-based approach and believe that Invivyd is poised to make a meaningful difference in the lives of thousands of vulnerable people in the United States who have been without access to a mAb for COVID-19 prevention for far too long |
| While VYD222 is an important near-term value driver for Invivyd, we believe INVYMAB is the engine which holds the potential to power our success for years to come |
| We believe that this result underscores the ongoing market opportunity |
| But more importantly, it would be a major advancement for the immunocompromised people we serve |
| And so we are very confident that using that as an endpoint with something that the FDA was aligned on for an EUA submission, again, assuming that the data supports the outcome |
| This seasoned team has collectively launched multiple successful products to address infectious disease |
| With a step wide approach, we believe that we can be very effective in getting VYD222 to key health systems and populations with a relatively small sales option |
| So we're very excited to have fully enrolled the study |
| We see a clear opportunity to impactfully enter the market, utilizing an efficient sales footprint to target certain subgroups of patients and providers initially and expand to additional groups over time |
| I'm excited to have joined the Invivyd team at such a potentially transformative period for the company |
| These data underscore the heavy human and financial toll that COVID-19 takes on this population and serve as a powerful motivation for us to get VYD222 and future antibodies authorized and available as quickly as possible for vulnerable individuals |
| Jeremy has more than 20 years of commercial leadership experience across all stages of product life cycle |
| While there is much work ahead of us, we are very pleased with our progress to date and look forward to sharing more details in the quarters ahead |
| The speed and efficiency of our progress are a testament to the dedication and focus of the outstanding team we have assembled and speak clearly to the fact that COVID-19 remains a significant health concern, particularly for immunocompromised individuals in the U.S |
| Based on our extensive market research, we believe there is a significant market opportunity with more than 9 million immunocompromised people at risk for severe COVID-19 in the U.S |
| At the top far right of the chart, you can see that there are approximately 485,000 people who are at the highest risk and have the highest expected uptake based on our market research |
| And as Jeremy mentioned, partly that's because these are the people who are the highest risk and certainly are also the ones who are expected to have the highest uptake |
| That's precisely why we have strategically positioned ourselves to keep pace with viral evolution through our proprietary platform approach, which we trademarked INVYMAB |
| To prepare for the potential launch of VYD222, our teams have also been engaging in appropriate scientific exchange with the medical community and key opinion leaders, and we are raising awareness of monoclonal antibodies for COVID-19 with various patient groups |
| Thank you very much, and have a good evening |
| We also continue to engage in constructive dialogue with the FDA regarding potential pathways that would enable us to fully leverage our INVYMAB platform approach to rapidly and perpetually deliver monoclonal antibody candidates |
| And then it also represents an efficient way for us to bring the product to market, looking at contract sales forces, et cetera, given the relatively consolidated group of people that these folks are, that we could look to target |
| The INVYMAB platform combines state-of-the-art viral surveillance and predictive modeling with advanced antibody engineering through our internal expertise and collaborations, such as our partnership with Adimab |
| During a short time with Invivyd, he has already proven himself to be a tremendous addition to our executive team and his knowledge and leadership will be invaluable to us as we prepare for a potential transition to a revenue-generating commercial company |
| Statement |
|---|
| They face distinct risks and challenges, which remain as acute today as they did during the height of the pandemic |
Please consider a small donation if you think this website provides you with relevant information